Fairvalue-Calculator Fairvalue-Calculator
EN DE

AmCad BioMed Corporation (4188) Fair Value & Analysis

Healthcare · IE · Market cap 668M UYU

Price10.55 UYU
Fair Value4.87 UYU
Upside-53.8%
Quality80/100
Evidence: Low Range 3.22 UYU – 6.09 UYU

Analysis

AmCad BioMed Corporation (4188) currently trades at 10.55 UYU, while our model-based Fair Value estimate is 4.87 UYU — implying the stock looks roughly 53.8% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company's products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA-cleared ultrasound systems; and AmCAD-UB, an AI Solution for Breast Lesion Detection. The company was incorporated in 2008 and is based in Taipei City, Taiwan.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -83% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +19%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.